GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

senaparib   Click here for help

GtoPdb Ligand ID: 11199

Synonyms: IMP-4297 | IMP4297 | Paishuning® (China)
Approved drug
senaparib is an approved drug
Compound class: Synthetic organic
Comment: Senaparib (IMP4297) is an oral poly(ADP-ribose) polymerase 1 (PARP1) inhibitor [1] that is being developed in a joint venture between IMPACT Therapeutics and Junshi Biosciences, for the treatment of BRCA-mutated solid tumours. It is one of the chemical structures claimed in patent WO2012130166A1 [2].

senaparib is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 104.19
Molecular weight 478.16
XLogP 3.56
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES Fc1ccc(cc1C(=O)N1CCN(CC1)c1ncccn1)Cn1c(=O)[nH]c(=O)c2c1cccc2F
Isomeric SMILES Fc1ccc(cc1C(=O)N1CCN(CC1)c1ncccn1)Cn1c(=O)[nH]c(=O)c2c1cccc2F
InChI InChI=1S/C24H20F2N6O3/c25-17-6-5-15(14-32-19-4-1-3-18(26)20(19)21(33)29-24(32)35)13-16(17)22(34)30-9-11-31(12-10-30)23-27-7-2-8-28-23/h1-8,13H,9-12,14H2,(H,29,33,35)
InChI Key VBTUJTGLLREMNW-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Senaparib (IMP4297) was progressed through to Phase 3 evaluation for potential as maintenance treatment in patients with advanced, BRCA1/2 mutated ovarian cancer, following first-line chemotherapy. First approval was granted by the Chinese NMPA in January 2025, indicated to treat advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03508011 A Study of IMP4297 in Patients With Advanced Solid Tumors Phase 1 Interventional Impact Therapeutics, Inc.
NCT04089189 Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer Phase 2 Interventional Impact Therapeutics, Inc.
NCT04169997 A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer Phase 3 Interventional Impact Therapeutics, Inc. In this study senaparib was found to significantly improve progression-free survival in patients with advanced ovarian cancer. Senaparib is proposed as a maintenance treatment for these patients after a response to first-line chemotherapy. 3